Overall, the above-mentioned studies suggest potential protective effects of GHRH antagonists against systemic hyperinflammation and sepsis-induced ARDS, main characteristics of severe COVID-19 (2); however, the role of these peptides in SARS-CoV-2-induced inflammation remains unexplored. Here, GHRH is linked to Sepsis.